These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 16322083

  • 21. Influenza vaccination of patients with systemic lupus erythematosus: safety and immunogenecity issues.
    Abu-Shakra M, Press J, Buskila D, Sukenik S.
    Autoimmun Rev; 2007 Sep; 6(8):543-6. PubMed ID: 17854746
    [Abstract] [Full Text] [Related]

  • 22. Antibody response to influenza immunization in patients with systemic lupus erythematosus.
    Mercado U.
    J Rheumatol; 2003 Oct; 30(10):2295; author reply 2295-6. PubMed ID: 14528534
    [No Abstract] [Full Text] [Related]

  • 23. Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers.
    Iorio AM, Camilloni B, Basileo M, Neri M, Lepri E, Spighi M.
    Gerontology; 2007 Oct; 53(6):411-8. PubMed ID: 17975317
    [Abstract] [Full Text] [Related]

  • 24. Immune response to influenza vaccination in community-dwelling Chinese elderly persons.
    Hui SL, Chu LW, Peiris JS, Chan KH, Chu D, Tsui W.
    Vaccine; 2006 Jun 19; 24(25):5371-80. PubMed ID: 16713661
    [Abstract] [Full Text] [Related]

  • 25. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus.
    Mathian A, Devilliers H, Krivine A, Costedoat-Chalumeau N, Haroche J, Huong DB, Wechsler B, Hervier B, Miyara M, Morel N, Le Corre N, Arnaud L, Piette JC, Musset L, Autran B, Rozenberg F, Amoura Z.
    Arthritis Rheum; 2011 Nov 19; 63(11):3502-11. PubMed ID: 21811996
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases.
    Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, Arad U, Brill A, Paran D, Levartovsky D, Wigler I, Caspi D, Mandelboim M.
    Arthritis Care Res (Hoboken); 2011 Jul 19; 63(7):1062-7. PubMed ID: 21425247
    [Abstract] [Full Text] [Related]

  • 27. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients.
    de Roux A, Marx A, Burkhardt O, Schweiger B, Borkowski A, Banzhoff A, Pletz MW, Lode H.
    Vaccine; 2006 Mar 06; 24(10):1537-42. PubMed ID: 16288937
    [Abstract] [Full Text] [Related]

  • 28. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.
    Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, Klimov A, Keitel WA, Nichol KL, Carr WW, Treanor JJ, Walter Reed Health Care System Influenza Vaccine Consortium.
    Arch Intern Med; 2008 Dec 08; 168(22):2405-14. PubMed ID: 19064822
    [Abstract] [Full Text] [Related]

  • 29. [Simultaneous vaccination against influenza and invasive pneumococcal disease in chronic dialysis patients].
    Trmal J, Havlícková M, Bícová R, Bitterová Z, Kelerová J.
    Epidemiol Mikrobiol Imunol; 2005 Aug 08; 54(3):123-8. PubMed ID: 16173523
    [Abstract] [Full Text] [Related]

  • 30. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951
    [Abstract] [Full Text] [Related]

  • 31. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
    Kapetanovic MC, Saxne T, Nilsson JA, Geborek P.
    Rheumatology (Oxford); 2007 Apr 27; 46(4):608-11. PubMed ID: 17114801
    [Abstract] [Full Text] [Related]

  • 32. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
    McLaurin EY, Holliday SL, Williams P, Brey RL.
    Neurology; 2005 Jan 25; 64(2):297-303. PubMed ID: 15668428
    [Abstract] [Full Text] [Related]

  • 33. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
    Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y.
    Vaccine; 2009 Jan 14; 27(3):454-9. PubMed ID: 19022318
    [Abstract] [Full Text] [Related]

  • 34. Efficacy of influenza vaccination in adult liver transplant recipients.
    Soesman NM, Rimmelzwaan GF, Nieuwkoop NJ, Beyer WE, Tilanus HW, Kemmeren MH, Metselaar HJ, de Man RA, Osterhaus AD.
    J Med Virol; 2000 May 14; 61(1):85-93. PubMed ID: 10745238
    [Abstract] [Full Text] [Related]

  • 35. Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies.
    Abu-Shakra M, Press J, Sukenik S, Buskila D.
    Clin Rheumatol; 2002 Sep 14; 21(5):369-72. PubMed ID: 12223983
    [Abstract] [Full Text] [Related]

  • 36. Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients.
    Vogtländer NP, Brown A, Valentijn RM, Rimmelzwaan GF, Osterhaus AD.
    Vaccine; 2004 Jun 02; 22(17-18):2199-201. PubMed ID: 15149777
    [Abstract] [Full Text] [Related]

  • 37. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease.
    Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN.
    Clin Gastroenterol Hepatol; 2007 Jul 02; 5(7):851-6. PubMed ID: 17544875
    [Abstract] [Full Text] [Related]

  • 38. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination.
    Sugimura T, Ito Y, Tananari Y, Ozaki Y, Maeno Y, Yamaoka T, Kudo Y.
    Vaccine; 2008 May 23; 26(22):2700-5. PubMed ID: 18436353
    [Abstract] [Full Text] [Related]

  • 39. Influenza vaccination in patients with breast cancer: a case-series analysis.
    Vilar-Compte D, Cornejo P, Valle-Salinas A, Roldán-Marin R, Iguala M, Cervantes Y, López I.
    Med Sci Monit; 2006 Aug 23; 12(8):CR332-6. PubMed ID: 16865064
    [Abstract] [Full Text] [Related]

  • 40. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
    Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y.
    Scand J Immunol; 2006 Apr 23; 63(4):299-303. PubMed ID: 16623930
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.